https://www.selleckchem.com/products/sn-38.html
00001). Additionally, SGLT2 inhibitors showed a significant increase in bilirubin levels (WMD 0.64 U/L, 95 % CI 0.27, 1.00, I2 = 53 %, p less then 0.0006. Finally, no significant changes were found on albumin levels (WMD 0.13 U/L, 95 % CI -0.06, 0.32, I2 = 53 %, p less then 0.0006) after SGLT2 inhibitors treatment. In conclusion, our results suggest that treatment with SGLT2 inhibitors exerts a beneficial effect on liver function tests through decreased ALT, AST, AP, and GGT concentrations.The role of high mobility group box 1 (HMGB1) has
Like
Comment
Share
